TFF Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing technology platform. Co. has two product candidates under development, TFF Voriconazole Inhalation Powder and TFF Tacrolimus Inhalation Powder. Co. is engaged in the joint development of an inhaled SARS-CoV2 Monoclonal Antibody in collaboration with Augmenta Bioworks, Inc. and a dry powder formulation of niclosamide in collaboration agreement with UNION therapeutics A/S. Co. is also engaged in the analysis and testing of dry powder formulations of several drugs and vaccines through topical, ocular and nasal applications. The TFFP stock yearly return is shown above.
The yearly return on the TFFP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TFFP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|